Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Articles in Fierce Healthcare and HealthExec referenced a study published in the February 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Screening for Health Literacy, Social Determinants, and Discrimination in Health Plans,” found that calling patients at the time of enrollment in a health plan could help in collecting health literacy data.
A study titled “Characterizing Telehealth Use in the US: Analysis of the 2022 Health Information National Trends Survey,” published in the January 2024 Health Information Technology issue of AJMC, was referenced in an article from Psychiatric Times. The study determined that identifying the motivation behind a patient’s use of telehealth could help shed light on the value of telehealth services.
An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Review: COVID-19 Pandemic Impact on Clinical Outcomes in Patients With Diabetes,” covered a review that found that COVID-19 disruptions on clinical outcomes were more pronounced in patients with diabetes if they were female, younger, and part of a racial or ethnic minority group.
AHIP’s daily SmartBrief Newsletter referenced an article published on AJMC.com. The article, “Salt Substitute Reduces Incidence of Hypertension in Older Adults,” reported on a study that found that a salt substitute reduced hypertension without increasing hypotension.
An article from Medriva referenced a contributor article published on AJMC.com. The article, “Contributor: Navigating Health Equity in 2024: The Evolution of Accountability, Part 2,” discussed the importance of accreditations when addressing health disparities and promoting health equity.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More